BRCA1 and neoplasm: Poly ADP‐ribose polymerase inhibitor (PARPi) is a potentially synthetic lethal effect agent for the therapy of cancers characterized by specific DNA‐repair defects, such as tumor cells that contain BRCA1 and/or BRCA2 (BRCA1/2) mutations and present defects in homologous recombination repair.1, 2, 3